Terray Therapeutics, a pioneering biotechnology company dedicated to revolutionizing the small molecule therapeutics landscape, has successfully raised an impressive $120 million in a recent funding round. This substantial investment highlights the confidence investors have in Terray’s innovative approach to drug discovery, which harnesses the power of ultra-high throughput experimentation and generative AI to explore a vast array of molecules and biological targets. At the core of Terray's platform is a seamless integration of cutting-edge technologies, including automation and nanotechnology, aimed at significantly enhancing the efficiency and effectiveness of the small molecule drug development process. With this new funding, Terray plans to accelerate its ambitious research initiatives, enabling the company to further refine its revolutionary platform and expand its portfolio of potential therapeutics that can address currently unmet medical needs. By focusing on an iterative methodology that produces vast amounts of precise, purpose-built data, Terray is set to not only improve the cost and speed of drug discovery but also elevate the overall success rate in bringing vital new therapies to market. As the biotech industry grapples with challenges in traditional drug development, Terray Therapeutics stands at the forefront of a much-needed transformation, ready to deliver groundbreaking solutions that could reshape healthcare as we know it. This funding round marks a pivotal moment in their journey, reinforcing their commitment to redefining small molecule therapeutics for a healthier future.
Terray Therapeutics Secures $120M in Series B Funding to Revolutionize Small Molecule Therapeutics Development
Recently funded · $120.0M Series bPharmaceuticals
Get the full Terray Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Aisot Technologies
Aisot Technologies is a Zurich-based AI company pioneering advanced, AI-driven investment solutions. Spun out of ETH Zurich in 2021, aisot leverages machine learning, large language models (LLMs), and quantitative methods to deliver precise, real-time investment insights. Its AI Insights Platform empowers asset managers, funds, family offices, and treasuries to anticipate market trends, optimize strategies, and mitigate risk. Recognized across Europe and the U.S., aisot partners with leading financial institutions to redefine quantitative investment management.
$2.5M Seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  NEW ID | Series b | $705.2K | today |
| 2 |  Arist United States | Series b | $14.1M | today |
| 3 |
